Simioni P, Sanson B J, Prandoni P, Tormene D, Friederich P W, Girolami B, Gavasso S, Huisman M V, Büller H R, Wouter ten Cate J, Girolami A, Prins M H
Department of Medical and Surgical Sciences, University Hospital of Padua, Italy.
Thromb Haemost. 1999 Feb;81(2):198-202.
The risk of spontaneous or risk-period related venous thromboembolism in family members of symptomatic carriers of antithrombin (AT), protein C (PC) or protein S (PS) defects, as well as of the Factor V Leiden mutation is still undefined. We performed a retrospective cohort study in family members (n = 793) of unselected patients with a documented venous thromboembolism and one of these deficiencies to make an estimate of this risk. The annual incidences of total and spontaneous venous thromboembolic events in carriers of AT, PC or PS defects (n = 181) were 1.01% and 0.40%, respectively, as compared to 0.10% and 0.04% in non-carriers, respectively (relative risks both 10.6). In carriers of Factor V Leiden (n = 224), the annual incidences of total and spontaneous venous thromboembolism were 0.28% and 0.11%, respectively, as compared to 0.09% and 0.04% in non-carriers, respectively (relative risks 2.8 and 2.5). Additional risk factors (immobilisation, surgery and trauma: oral contraceptive use; and pregnancy/ post-partum) increased the risk of thrombosis in carriers of AT, PC and PS defects as compared to non-carriers (relative risks 8.3, 6.4 and 8.2, respectively). Oral contraceptive use and pregnancy/ post-partum period increased the risk of thrombosis in carriers of Factor V Leiden to 3.3-fold and 4.2-fold, respectively, whereas other risk factors had only a minor effect. These data lend some support to the practice of screening family members of symptomatic carriers of a AT, PC and PS deficiency. For family members of symptomatic carriers of Factor V Leiden, screening does not seem to be justified except for women in fertile age.
抗凝血酶(AT)、蛋白C(PC)或蛋白S(PS)缺陷以及凝血因子V莱顿突变的有症状携带者的家庭成员发生自发性或与风险期相关的静脉血栓栓塞的风险仍不明确。我们对未选择的有静脉血栓栓塞记录且存在上述其中一种缺陷的患者的家庭成员(n = 793)进行了一项回顾性队列研究,以评估这种风险。AT、PC或PS缺陷携带者(n = 181)中,总的和自发性静脉血栓栓塞事件的年发生率分别为1.01%和0.40%,而非携带者分别为0.10%和0.04%(相对风险均为10.6)。在凝血因子V莱顿携带者(n = 224)中,总的和自发性静脉血栓栓塞的年发生率分别为0.28%和0.11%,而非携带者分别为0.09%和0.04%(相对风险分别为2.8和2.5)。与非携带者相比,其他风险因素(固定不动、手术和创伤、口服避孕药使用以及妊娠/产后)增加了AT、PC和PS缺陷携带者的血栓形成风险(相对风险分别为8.3、6.4和8.2)。口服避孕药使用以及妊娠/产后时期使凝血因子V莱顿携带者的血栓形成风险分别增加至3.3倍和4.2倍,而其他风险因素的影响较小。这些数据为对AT、PC和PS缺陷有症状携带者的家庭成员进行筛查的做法提供了一些支持。对于凝血因子V莱顿有症状携带者的家庭成员,除育龄女性外,筛查似乎没有必要。